Unknown

Dataset Information

Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation.


ABSTRACT:

Introduction

Lenvatinib is approved for the treatment of patients with metastatic or recurrent hepatocellular carcinoma (HCC); however, clinical outcomes of lenvatinib therapy in patients with post-liver transplantation (LT) HCC recurrence remain unclear. We investigated the efficacy and safety of lenvatinib in patients with post-LT HCC recurrence.

Methods

This multinational, multicenter, retrospective study included 45 patients with recurrent HCC after LT who received lenvatinib at six institutions in three countries (Korea, Italy, and Hong Kong) from June 2017 to October 2021.

Results

At the time of lenvatinib initiation, 95.6% (n = 43) of patients had Child-Pugh A status, and 35 (77.8%) and 10 (22.2%) participants were classified as having albumin-bilirubin (ALBI)

SUBMITTER: Bang K 

PROVIDER: S-EPMC9939097 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature